Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

NCT06984328 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

1

Enrollment

INDUSTRY

Sponsor class

Conditions

Cutaneous Melanoma
Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID)
Metastatic Cutaneous Melanoma (Stage IV)

Interventions

BIOLOGICAL: Acasunlimab
BIOLOGICAL: Pembrolizumab

Sponsor

Genmab